Abstract
Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ). Because PPAR-γ initiates a variety of antiinflammatory responses, the effect on myocardial ischemia is to be elucidated. The left anterior descending arteries were ligated to induce myocardial infarction in rats. The animals were assigned to 4 groups: (1) control (saline, n = 6), (2) telmisartan (10 mg·kg·d, n = 6), (3) telmisartan + GW9662 (PPAR-γ-antagonist) (10 mg·kg·d of telmisartan and 1 mg·kg·d of GW9662, n = 6), and (4) amlodipine (10 mg·kg·d, n = 8) groups. Telmisartan reduced mean blood pressure compared with that in the control group. There was no statistical difference among the telmisartan, telmisartan + GW9662 and amlodipine groups. The end-diastolic left ventricular diameter was smaller in telmisartan group compared with that in the control group; GW9662 negated the effect of telmisartan. The thickness of the ventricular septum was kept in the telmisartan group compared with that in the control group; GW9662 negated the effect. Histopathologic analyses showed that telmisartan suppressed myocardial fibrosis compared with that of the control, whereas GW9662 negated the telmisar...Continue Reading
References
Mar 1, 1991·Circulation Research·G OlivettiP Anversa
Nov 18, 1991·The American Journal of Cardiology·P AnversaJ M Capasso
Jan 1, 1991·Circulation·R E GoldsteinS Nattel
May 21, 1998·Journal of Cardiovascular Pharmacology·K TaylorM A Konstam
Jul 11, 1998·Cardiovascular Research·T ShimadaJ Yoshikawa
Mar 10, 2004·Hypertension·Stephen C BensonTheodore W Kurtz
May 1, 2004·Circulation·Michael SchuppUlrich Kintscher
Dec 25, 2004·Medical Hypotheses·S Yamagishi, M Takeuchi
Feb 16, 2005·The Journal of Clinical Investigation·Shin-ichiro MatsumuraYasunori Okada
Dec 20, 2005·Cardiovascular Research·Davy VanhoutteStephane Heymans
Mar 29, 2006·Hypertension·Ken SugimotoTheodore W Kurtz
Dec 13, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Marina R BergmanDavid H Lovett
Feb 19, 2008·British Journal of Pharmacology·G-H HaoN-P Wang
Apr 18, 2008·Journal of Cardiovascular Pharmacology·Binhui Liang, Frans H H Leenen
Apr 26, 2008·American Journal of Hypertension·Naohiko KobayashiHiroaki Matsuoka
May 14, 2008·Journal of Hypertension·Ken SugimotoMichal Pravenec
Oct 16, 2008·Protein and Peptide Letters·Sho-ichi YamagishiHiroyoshi Inoue
Mar 24, 2010·Chemico-biological Interactions·Sameer GoyalDharamvir Singh Arya
Jul 3, 2010·Stroke; a Journal of Cerebral Circulation·Kazuo WashidaRyosuke Takahashi
Citations
Mar 6, 2013·Canadian Journal of Physiology and Pharmacology·Satomi KagotaKazumasa Shinozuka
Dec 22, 2015·Mediators of Inflammation·Hasahya TonyYucheng Zhong
Aug 8, 2015·Neurourology and Urodynamics·Kenichi MoriNaoki Yoshimura
May 1, 2016·Pharmacology & Therapeutics·Martin C MichelYong Huo
Aug 16, 2016·Cardiovascular Diabetology·Wei-Ting ChangZhih-Cherng Chen
Apr 5, 2018·Clinical and Experimental Pharmacology & Physiology·Wei-Ting Chang, Sheng-Nan Wu
Jun 18, 2017·Frontiers in Pharmacology·Benita L McVicker, Robert G Bennett
Jan 24, 2020·Cells·Matthias L RiessAmadou K S Camara
Oct 7, 2020·Pharmacology & Therapeutics·Qirong LuMaría-Aránzazu Martínez